Kestra Medical Technologies (NASDAQ:KMTS) Insider Brian Daniel Webster Sells 15,000 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $22.80, for a total value of $342,000.00. Following the sale, the insider owned 394,786 shares in the company, valued at $9,001,120.80. This trade represents a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $26.59, for a total value of $398,850.00.

Kestra Medical Technologies Stock Performance

Shares of KMTS stock opened at $23.00 on Wednesday. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.26. Kestra Medical Technologies, Ltd. has a 12-month low of $13.25 and a 12-month high of $30.00. The business’s 50 day moving average is $25.54 and its two-hundred day moving average is $22.22. The company has a market capitalization of $1.34 billion and a P/E ratio of -7.26.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of institutional investors have recently bought and sold shares of KMTS. Millennium Management LLC grew its stake in shares of Kestra Medical Technologies by 534.7% in the 3rd quarter. Millennium Management LLC now owns 219,706 shares of the company’s stock valued at $5,220,000 after buying an additional 185,090 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Kestra Medical Technologies in the third quarter valued at approximately $185,000. Bank of America Corp DE lifted its holdings in Kestra Medical Technologies by 161.2% in the third quarter. Bank of America Corp DE now owns 21,591 shares of the company’s stock valued at $513,000 after acquiring an additional 13,325 shares during the last quarter. Alliancebernstein L.P. grew its position in Kestra Medical Technologies by 13.7% in the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after acquiring an additional 179,885 shares during the period. Finally, Longaeva Partners L.P. increased its stake in Kestra Medical Technologies by 342.7% during the third quarter. Longaeva Partners L.P. now owns 136,182 shares of the company’s stock worth $3,236,000 after acquiring an additional 105,421 shares during the last quarter.

Analyst Upgrades and Downgrades

KMTS has been the subject of several recent analyst reports. BTIG Research initiated coverage on shares of Kestra Medical Technologies in a report on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price target for the company. Piper Sandler boosted their target price on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, December 24th. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Sunday, September 28th. Finally, The Goldman Sachs Group set a $24.00 target price on Kestra Medical Technologies in a report on Friday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.00.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.